{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:59:04Z","timestamp":1763643544392,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"am","delay-in-days":292,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DP1 DA041722","R01 AG056259","R01 AG066750","R01 AG073418","R01 DA048882","R01 NS086890","R35 AG071734","R56 AG065372","RF1 AG057409"],"award-info":[{"award-number":["DP1 DA041722","R01 AG056259","R01 AG066750","R01 AG073418","R01 DA048882","R01 NS086890","R35 AG071734","R56 AG065372","RF1 AG057409"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.coph.2022.102267","type":"journal-article","created":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T18:06:01Z","timestamp":1658340361000},"page":"102267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Towards development of disease-modifying therapy for Alzheimer's disease using redox chemical biology pathways"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3490-1259","authenticated-orcid":false,"given":"Stuart A.","family":"Lipton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2022.102267_bib1","doi-asserted-by":"crossref","first-page":"11908","DOI":"10.1073\/pnas.172398899","article-title":"Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants","volume":"99","author":"Dinkova-Kostova","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coph.2022.102267_bib2","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.50333","article-title":"Mechanisms of hyperexcitability in Alzheimer's disease hiPSC-derived neurons and cerebral organoids vs isogenic controls","volume":"8","author":"Ghatak","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.coph.2022.102267_sref3","first-page":"1038","article-title":"NitroSynapsin ameliorates hypersynchronous neural network activity in Alzheimer hiPSC models","volume":"10","author":"Ghatak","year":"2020","journal-title":"Mol Psychiatr"},{"key":"10.1016\/j.coph.2022.102267_sref4","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1146\/annurev-pharmtox-032320-015420","article-title":"Novel therapeutic approach for excitatory\/inhibitory imbalance in neurodevelopmental and neurodegenerative diseases","volume":"61","author":"Ghatak","year":"2021","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.coph.2022.102267_bib5","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.freeradbiomed.2015.07.147","article-title":"Nrf2--a therapeutic target for the treatment of neurodegenerative diseases","volume":"88","author":"Johnson","year":"2015","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.coph.2022.102267_bib6","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nrd1958","article-title":"Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond","volume":"5","author":"Lipton","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.coph.2022.102267_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.389","article-title":"Therapeutic advantage of pro-electrophilic drugs to activate the Nrf2\/ARE pathway in Alzheimer's disease models","volume":"7","author":"Lipton","year":"2016","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.coph.2022.102267_bib8","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.neuron.2013.05.005","article-title":"Aberrant protein S-nitrosylation in neurodegenerative diseases","volume":"78","author":"Nakamura","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.coph.2022.102267_bib9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.tips.2015.10.002","article-title":"Protein S-nitrosylation as a therapeutic target for neurodegenerative diseases","volume":"37","author":"Nakamura","year":"2016","journal-title":"Trends Pharmacol"},{"key":"10.1016\/j.coph.2022.102267_bib10","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.tem.2017.10.004","article-title":"\u2018SNO\u2019-storms compromise protein activity and mitochondrial metabolism in neurodegenerative disorders","volume":"28","author":"Nakamura","year":"2017","journal-title":"Trends Endocrinol Metabol"},{"key":"10.1016\/j.coph.2022.102267_sref11","first-page":"35531","article-title":"Protein transnitrosylation signaling networks contribute to inflammaging and neurodegenerative disorders","author":"Nakamura","year":"2021","journal-title":"Antioxidants Redox Signal"},{"key":"10.1016\/j.coph.2022.102267_sref12","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.freeradbiomed.2021.07.002","article-title":"Protein S-nitrosylation and oxidation contribute to protein misfolding in neurodegeneration","volume":"172","author":"Nakamura","year":"2021","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.coph.2022.102267_bib13","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.nbd.2019.03.029","article-title":"NitroSynapsin for the treatment of neurological manifestations of tuberous sclerosis complex in a rodent model","volume":"127","author":"Okamoto","year":"2019","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.coph.2022.102267_bib14","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1001\/archneurol.2009.15","article-title":"Epilepsy and cognitive impairments in Alzheimer disease","volume":"66","author":"Palop","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1016\/j.coph.2022.102267_bib15","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/nn.2583","article-title":"Amyloid-\u03b2-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks","volume":"13","author":"Palop","year":"2010","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.coph.2022.102267_bib16","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/nrn.2016.141","article-title":"Network abnormalities and interneuron dysfunction in Alzheimer disease","volume":"17","author":"Palop","year":"2016","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.coph.2022.102267_bib17","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.canlet.2015.07.005","article-title":"Diterpenes from rosemary (Rosmarinus officinalis): defining their potential for anti-cancer activity","volume":"367","author":"Petiwala","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1016\/j.coph.2022.102267_bib18","doi-asserted-by":"crossref","first-page":"7847","DOI":"10.1167\/iovs.12-10793","article-title":"Protective effect of carnosic acid, a pro-electrophilic compound, in models of oxidative stress and light-induced retinal degeneration","volume":"53","author":"Rezaie","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.coph.2022.102267_bib19","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/j.1471-4159.2007.05039.x","article-title":"Carnosic acid, a catechol-type electrophilic compound, protects neurons both in\u00a0vitro and in\u00a0vivo through activation of the Keap1\/Nrf2 pathway via S-alkylation of targeted cysteines on Keap1","volume":"104","author":"Satoh","year":"2008","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.coph.2022.102267_bib20","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.12688\/f1000research.12111.1","article-title":"Recent advances in understanding NRF2 as a druggable target: development of pro-electrophilic and non-covalent NRF2 activators to overcome systemic side effects of electrophilic drugs like dimethyl fumarate","volume":"6","author":"Satoh","year":"2017","journal-title":"F1000Res"},{"key":"10.1016\/j.coph.2022.102267_bib21","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.freeradbiomed.2013.07.022","article-title":"Nrf2\/ARE-mediated antioxidant actions of pro-electrophilic drugs","volume":"65","author":"Satoh","year":"2013","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.coph.2022.102267_sref22","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3390\/antiox11010124","article-title":"Potential therapeutic use of the rosemary diterpene carnosic acid for Alzheimer's disease, Parkinson's disease, and Long-COVID through NRF2 activation to counteract the NLRP3 inflammasome","volume":"11","author":"Satoh","year":"2022","journal-title":"Antioxidants"},{"key":"10.1016\/j.coph.2022.102267_bib23","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1471-4159.2011.07449.x","article-title":"Dual neuroprotective pathways of a pro-electrophilic compound via HSF-1-activated heat-shock proteins and Nrf2-activated phase 2 antioxidant response enzymes","volume":"119","author":"Satoh","year":"2011","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.coph.2022.102267_bib24","doi-asserted-by":"crossref","DOI":"10.1177\/1759091415593294","article-title":"Nrf2 and HSF-1 pathway activation via hydroquinone-based pro-electrophilic small molecules is regulated by electrochemical oxidation potential","volume":"7","author":"Satoh","year":"2015","journal-title":"ASN Neuro"},{"key":"10.1016\/j.coph.2022.102267_bib25","doi-asserted-by":"crossref","first-page":"E2518","DOI":"10.1073\/pnas.1306832110","article-title":"A\u03b2 induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss","volume":"110","author":"Talantova","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coph.2022.102267_sref26","doi-asserted-by":"crossref","unstructured":"Trudler D, Ghatak S, Parker J, Talantova M, Grabauskas T, Noveral SM, Teranaka M, Luevanos M, Dolatabadi N, Bakker C, Lopez K, Sultan A, Chan A, Yongwook C, kawaguchi R, Schork N, Stankiewicz P, Garcia-Bassets I, Kkozbial P, Rosenfeld MG, Nakanishi N, Geschwind DH, Chan SF, Amabasudhan R, Lipton SA. Aberrant gliogenesis and excitation in MEF2C autism patient hiPSC-neurons and cerebral organoids. bioRxiv doi: 10.1101\/2020.11.19.387639.","DOI":"10.1101\/2020.11.19.387639"},{"key":"10.1016\/j.coph.2022.102267_bib27","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1038\/s41467-017-01563-8","article-title":"NitroSynapsin therapy for the mouse MEF2C haploinsufficiency model of human autism","volume":"8","author":"Tu","year":"2017","journal-title":"Nat Commun"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489222000947?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489222000947?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:56:28Z","timestamp":1761461788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489222000947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":27,"alternative-id":["S1471489222000947"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2022.102267","relation":{},"ISSN":["1471-4892"],"issn-type":[{"type":"print","value":"1471-4892"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Towards development of disease-modifying therapy for Alzheimer's disease using redox chemical biology pathways","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2022.102267","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102267"}}